Phase I/II, multicenter, open-label study of intratumoral/intralesional administration of the retinoic acid–inducible gene I (RIG-I) activator MK-4621 in patients with advanced or recurrent tumors

Autor:	Emiliano Calvo, Mark R. Middleton, Haojin Zhou, Martin Wermke, M. Niewel, Konstantin Dobrenkov, Victor Moreno, X. Zhao, Elliot Chartash
Rok vydání:	2018
Předmět:	0301 basic medicine business.industry RIG-I Activator (genetics) Hematology 03 medical and health sciences 030104 developmental biology Phase i ii Oncology Retinoic Acid Inducible Gene I Open label study Tretinoin Cancer research Medicine In patient business Gene medicine.drug
Zdroj:	Annals of Oncology. 29:viii712
ISSN:	0923-7534
DOI:	10.1093/annonc/mdy424.016
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::cffad67c471a5aab97b41874603e10d0 https://doi.org/10.1093/annonc/mdy424.016 Zobrazit plný text záznamu